Elevra Lithium (ASX: ELV) is a dual-listed North American-focused producer with growth assets, led by its Québec NAL operation. Recent share moves reflect capital raising, record production, index inclusion, improving lithium sentiment, while technicals show an uptrend nearing key resistance.
Minbos Resources surged after securing US$21.5 m+ in debt funding for its Cabinda Phosphate Project in Angola, boosting investor confidence in its move toward production. The market now eyes construction progress, though execution, funding, and ramp-up risks remain significant.
Neurizon Therapeutics (ASX: NUZ) is a clinical-stage biotech developing NUZ-001 for ALS and other neurodegenerative diseases. Despite promising data and global trials, the stock faces pressure from clinical delays, dilution, rising losses, and ongoing uncertainty typical of pre-revenue biotech companies.
Marmota (ASX: MEU) has surged back into focus after strong gains driven by high-grade drilling results from its Greenewood gold project in South Australia. Renewed exploration activity, rising gold prices, and aggressive drilling have boosted investor interest. The stock remains highly speculative but increasingly watched by ASX momentum traders.
Neuren Pharmaceuticals (ASX: NEU) is a rare-disease biotech generating revenue from DAYBUE while advancing NNZ-2591. After declines from regulatory and guidance setbacks, improving US rollout and technical strength suggest a recovery, with the stock forming higher lows and testing key resistance levels.
Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.
